#1 Clinical Trials Search in Europe

Anhydrous Cyclophosphamide

Anhydrous Cyclophosphamide is a chemotherapy drug being studied in several clinical trials for different types of blood cancers. These trials aim to evaluate its effectiveness and safety when used alone or in combination with other treatments for conditions like acute myeloid leukemia, Hodgkin lymphoma, and various rare B-cell malignancies. This article summarizes key information about ongoing clinical trials using Anhydrous Cyclophosphamide in cancer treatment.

Table of Contents

What is Cyclophosphamide?

Anhydrous Cyclophosphamide, commonly known as Cyclophosphamide, is a powerful medication used in the treatment of various cancers and autoimmune disorders. It belongs to a class of drugs called alkylating agents, which are used in chemotherapy[1]. Cyclophosphamide is also known by its brand names, which may vary depending on the country and manufacturer.

Medical Conditions Treated

Cyclophosphamide is used to treat a wide range of medical conditions, including:

  • Acute Myeloid Leukemia (AML): A type of blood and bone marrow cancer[1]
  • Classical Hodgkin Lymphoma: A cancer of the lymphatic system[2]
  • Waldenstrom Macroglobulinemia (WM): A rare type of blood cancer[3]
  • Richter Transformation (RT): A rare complication of chronic lymphocytic leukemia[4]
  • Burkitt Lymphoma (BL): A fast-growing type of non-Hodgkin lymphoma[5]
  • Hairy Cell Leukemia (HCL): A rare, slow-growing blood cancer[6]

How Cyclophosphamide Works

Cyclophosphamide is an alkylating agent, which means it works by damaging the DNA of cancer cells. This damage prevents the cells from dividing and multiplying, ultimately leading to their death. While Cyclophosphamide primarily targets rapidly dividing cancer cells, it can also affect healthy cells in the body, which is why it may cause side effects[1].

Administration and Dosage

Cyclophosphamide is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of administration can vary depending on the specific condition being treated, the patient’s body surface area, and other individual factors. Some common dosage ranges observed in clinical trials include:

  • 500-1250 mg/m² (milligrams per square meter of body surface area) per day[1][2]
  • Total doses ranging from 1500-9600 mg/m² over the course of treatment[3][4][5][6]

The duration of treatment can range from a few days to several months, depending on the specific treatment protocol and the patient’s response to therapy.

Side Effects and Precautions

As with any powerful medication, Cyclophosphamide can cause side effects. Some common side effects include:

  • Nausea and vomiting
  • Hair loss
  • Fatigue
  • Increased risk of infections
  • Changes in blood cell counts
  • Bladder irritation

More serious side effects can include an increased risk of developing other cancers, fertility problems, and damage to the heart or lungs. It’s important to discuss all potential risks and side effects with your healthcare provider[1].

Patients should be aware of certain precautions when taking Cyclophosphamide:

  • Inform your doctor about any other medications or supplements you’re taking
  • Avoid live vaccines while on treatment
  • Use effective contraception, as Cyclophosphamide can harm a developing fetus
  • Stay well-hydrated to help prevent bladder problems
  • Regular blood tests will be needed to monitor your health during treatment

Clinical Trials and Research

Cyclophosphamide is being studied in various clinical trials to improve its effectiveness and explore its use in different treatment regimens. Some ongoing research includes:

  • Combining Cyclophosphamide with newer targeted therapies or immunotherapies[1][2]
  • Using Cyclophosphamide as part of conditioning regimens before stem cell transplantation[1]
  • Exploring its use in rare blood cancers and lymphomas[3][4][5][6]

These studies aim to optimize treatment strategies, improve patient outcomes, and reduce side effects associated with Cyclophosphamide therapy.

Trial Number Cancer Type Trial Phase Key Objectives Dosage
2022-500783-35-00 Acute Myeloid Leukemia Not specified Evaluate event-free survival with CPX-351 and Gemtuzumab Ozogamicin 60 mg/kg (max daily), 120 mg/kg (max total)
2022-501180-40-00 Ewing Sarcoma Phase III Evaluate event-free survival with VinoCyc maintenance therapy 1200 mg/m² (max daily), 9600 mg/m² (max total)
2022-501259-10-00 Waldenstrom Macroglobulinemia Phase II Evaluate complete and very good partial response rates 750 mg/m² (max daily), 1500 mg/m² (max total)
2022-501260-18-00 Richter Transformation Phase II Evaluate objective response rate 750 mg/m² (max daily), 1500 mg/m² (max total)
2022-501261-46-00 Burkitt Lymphoma Phase II Evaluate objective response rate 750 mg/m² (max daily), 1500 mg/m² (max total)
2022-501262-21-00 Hairy Cell Leukemia Phase II Evaluate objective response rate 500 mg/m² (max daily), 1500 mg/m² (max total)
2022-501615-14-00 Classical Hodgkin Lymphoma Phase II Evaluate complete response rate 1250 mg/m² (max daily), 5000 mg/m² (max total)

FAQ

  • What is Anhydrous Cyclophosphamide? Anhydrous Cyclophosphamide is a chemotherapy drug used to treat various types of cancer, particularly blood cancers. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA of cancer cells to stop them from growing and dividing.
  • What types of cancer are being studied with Anhydrous Cyclophosphamide in these trials? The clinical trials are investigating Anhydrous Cyclophosphamide for several blood cancers, including acute myeloid leukemia, classical Hodgkin lymphoma, Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia.
  • How is Anhydrous Cyclophosphamide administered in these trials? In the clinical trials, Anhydrous Cyclophosphamide is typically administered through intravenous infusion. The dosage and frequency vary depending on the specific trial and cancer type being studied.
  • Are there any common side effects of Anhydrous Cyclophosphamide? While specific side effects are not detailed in the trial summaries, common side effects of cyclophosphamide can include nausea, vomiting, hair loss, and increased risk of infections. The trials are monitoring for adverse events and safety concerns.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary by trial but generally include adults with specific blood cancer diagnoses, adequate organ function, and no recent treatment with certain other therapies. Some trials have specific requirements related to prior treatments or disease stage.

Ongoing Clinical Trials on Anhydrous Cyclophosphamide

  • Study Comparing Two Drug Combinations for Blood Cancer Patients: Rabbit Anti-Human Thymocyte Immunoglobulin vs. Anhydrous Cyclophosphamide

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on STC-1010 and Drug Combination for Patients with Advanced or Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Early Diffuse Cutaneous Systemic Sclerosis: Comparing Stem Cell Transplantation with Cyclophosphamide, Filgrastim, and Mycophenolate Mofetil

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy The Netherlands Sweden

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Germany Greece Italy Poland

  • Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Hungary +5

  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy The Netherlands Spain +1

  • Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy The Netherlands Spain +1

Glossary

  • Anhydrous Cyclophosphamide: A chemotherapy drug used to treat various types of cancer, particularly blood cancers. It belongs to a class of drugs called alkylating agents.
  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.
  • Hodgkin Lymphoma: A type of cancer that affects the lymphatic system, part of the body's immune system.
  • Waldenstrom Macroglobulinemia (WM): A rare type of blood cancer that begins in the white blood cells called B lymphocytes.
  • Richter Transformation (RT): A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma where the cancer transforms into an aggressive form of lymphoma.
  • Burkitt Lymphoma: A rare but aggressive form of non-Hodgkin lymphoma that affects B cells in the lymphatic system.
  • Hairy Cell Leukemia: A rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes).
  • Intravenous Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Complete Response (CR): In cancer treatment, it refers to the disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-treating-acute-myeloid-leukemia-in-children-and-adolescents-using-cpx-351-gemtuzumab-ozogamicin-and-a-drug-combination/
  2. http://clinicaltrials.eu/trial/study-of-pembrolizumab-and-chemotherapy-for-patients-with-newly-diagnosed-classical-hodgkin-lymphoma/
  3. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-waldenstrom-macroglobulinemia-using-a-drug-combination/
  4. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-richter-transformation-rt/
  5. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-or-refractory-burkitt-lymphoma/
  6. http://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-refractory-hairy-cell-leukemia/